Article

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies

2024-07-19

Abstract excerpt

<h4>ABSTRACT</h4> Genomic loss of the transcriptional kinase CDK12 occurs in ∼6% of metastatic castration-resistant prostate cancers (mCRPC) and correlates with poor patient outcomes. Prior studies demonstrate that acute CDK12 loss confers a homologous recombination (HR) deficiency (HRd) phenotype via premature intronic polyadenylation (IPA) of key HR pathway genes, including ATM. However, mCRPC patients have n...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 78071128-5771-5e5c-b12a-2b0c7cfbbee4
DOI: 10.1101/2024.07.16.603734

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategiesDOI 10.1101/2024.07.16.603734Read

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.Semantic proximity Read

CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Semantic proximity Read

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.Semantic proximity Read

Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy.Semantic proximity Read

Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors.Semantic proximity Read

RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancerSemantic proximity Read

Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancerSemantic proximity Read

RNASEH2B loss and PARP inhibition in advanced prostate cancerSemantic proximity Read

CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancerSemantic proximity Read

Genomic aberration based molecular signatures efficiently characterize homologous recombination deficiency in prostate cancerSemantic proximity Read

Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancerSemantic proximity Read